GLP-1 receptor agonists like semaglutide and tirzepatide act on incretin pathways through GLP-1 and GIP receptors, with central appetite suppression and slowed gastric emptying as primary mechanisms
Finally, poor oral bioavailability, incomplete toxicology, uncertain long-term effects, and the absence of controlled human trials remain major limitations
These can include injection site irritation, headache, flushing or warmth, fatigue, mild gastrointestinal discomfort such as nausea, dizziness, or changes in appetite
The evidence was based on experimental data only briefly described in the patent and included models of: gastric ulcers, heart damage, liver damage, pancreatic injury, kidney damage, experimental diabetes, fever, edema, rhinitis, bone fracture, burns, skin wounds, hypersensitivity reactions, pupil dilation, colon injury, tumour growth, radiation injury, red blood cell development, fertility and lactation, tooth damage, several types of central and peripheral nerve damage, and survival from infection with Trichinosis (i.e., tapeworms) as well as several viruses
I only purchase with them
For 500mcg: draw to the 20 unit mark (0.20ml)
